Dyne Therapeutics Inc (DYN)
26.02
+0.06
(+0.23%)
USD |
NASDAQ |
May 10, 16:00
26.02
0.00 (0.00%)
After-Hours: 20:00
Dyne Therapeutics Cash from Investing (TTM): -123.59M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -123.59M |
December 31, 2023 | 83.31M |
September 30, 2023 | 76.35M |
June 30, 2023 | 115.19M |
March 31, 2023 | 116.40M |
December 31, 2022 | 87.20M |
September 30, 2022 | 67.73M |
Date | Value |
---|---|
June 30, 2022 | 13.22M |
March 31, 2022 | -11.65M |
December 31, 2021 | -137.89M |
September 30, 2021 | -182.88M |
June 30, 2021 | -180.19M |
March 31, 2021 | -173.82M |
December 31, 2020 | -45.66M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-182.88M
Minimum
Sep 2021
116.40M
Maximum
Mar 2023
-21.16M
Average
0.7855M
Median
Cash from Investing (TTM) Benchmarks
Solid Biosciences Inc | 9.689M |
Sana Biotechnology Inc | 32.06M |
Tenaya Therapeutics Inc | 48.72M |
Prime Medicine Inc | 18.71M |
CEL-SCI Corp | -0.3835M |